Clin2
NCT07471282Possibly a fitNot yet recruiting

Tenecteplase after incomplete clot removal for stroke

Stroke

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This study tests whether giving a clot-busting drug called tenecteplase directly into the brain's blood vessels can help complete the removal of a clot after a first attempt at mechanical extraction was only partially successful.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
344 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be at least 18 years old.
  • Your stroke symptoms must have started within the last 24 hours (or you were last known to be well then).
  • You must have a confirmed blockage in a large artery in the front part of your brain, and you already had a mechanical thrombectomy procedure that did not fully restore blood flow (the clot was partially removed).
  • You must have a stroke severity score (NIHSS) of 6 or higher, meaning at least moderate symptoms.
  • You must be able to give written permission (or have a guardian do it) to join the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06954155Recruiting· Phase 3
Tenecteplase for stroke treatment 24-72 hours after symptoms start

This trial tests if the clot-busting drug tenecteplase can help people with a moderate to severe stroke when given 24 to 72 hours after symptoms began. It aims to see if this later treatment window can improve recovery and reduce disability.

Beijing
NCT07476898Not yet recruiting· Phase 3
Precision clot treatment for disabling minor stroke with large vessel blockage beyond time window

This trial tests a specialized clot-removal treatment for people who had a mild but disabling stroke up to 24 hours ago and have a large artery blockage in the brain. The goal is to see if this precision therapy can help reduce disability and improve recovery.

Fuzhou, Fujian
NCT07603440Not yet recruiting· Phase 3
Clot-Busting Drug Plus Mechanical Removal for Large Strokes

This trial tests whether giving a clot-busting medication (tenecteplase) intravenously before mechanical thrombectomy—a procedure to physically remove a large blood clot from the brain—improves recovery better than thrombectomy alone in patients with large ischemic strokes.

Aix-en-Provence
NCT07375966Recruiting· Phase 2
Repeated clot-busting drug for stroke with large vessel block

This trial tests if giving a second dose of the clot-busting drug tenecteplase can help people whose stroke symptoms don't improve after the first dose, when a large or medium artery in the brain is still blocked. It may be an option for patients who cannot have a mechanical clot removal procedure.

Shenyang, Liaoning
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina
NCT06904911Recruiting· Phase 2
Study of tenecteplase into the artery after clot removal for stroke

This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.

Philadelphia, Pennsylvania

Hear when a new Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.